Ö. G. SEVİNDİK Et Al. , "IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia," Society of Hematologic Oncology Eighth Annual Meeting , Houston, United States Of America, 2020
SEVİNDİK, Ö. G. Et Al. 2020. IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia. Society of Hematologic Oncology Eighth Annual Meeting , (Houston, United States Of America).
SEVİNDİK, Ö. G., GEMİCİ, A., MUTLU, Y. G., BALIK AYDIN, B., & ÇAKIR, A., (2020). IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia . Society of Hematologic Oncology Eighth Annual Meeting, Houston, United States Of America
SEVİNDİK, Ömür Et Al. "IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia," Society of Hematologic Oncology Eighth Annual Meeting, Houston, United States Of America, 2020
SEVİNDİK, Ömür G. Et Al. "IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia." Society of Hematologic Oncology Eighth Annual Meeting , Houston, United States Of America, 2020
SEVİNDİK, Ö. G. Et Al. (2020) . "IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia." Society of Hematologic Oncology Eighth Annual Meeting , Houston, United States Of America.
@conferencepaper{conferencepaper, author={Ömür Gökmen SEVİNDİK Et Al. }, title={IBCL-386: Rituximab-Vemurafenib Combination for the Treatment of Relapsed/Refractory Hairy Cell Leukemia}, congress name={Society of Hematologic Oncology Eighth Annual Meeting}, city={Houston}, country={United States Of America}, year={2020}}